Health Care Delivery

Suicide has emerged as the leading cause of death among Asian American and Pacific Islander (AAPI) youths, a demographic that is rapidly growing in the United States.

Should the FDA require that new trial design proposals for perioperative regimens for resectable non–small cell lung cancer (NSCLC) include adequate within trial assessment?

Crystal S. Denlinger, MD, FACP, CEO of the National Comprehensive Cancer Network, discusses possible federal policies to help mitigate ongoing and future cancer drug shortages.

A recent study showed that the Myasthenia Gravis (MG) Symptoms PRO scales viably measure core symptoms of the disease.

This week, the Center on Health Equity & Access delved into the state of equity as it relates to national spending, ovarian cancer care, health technology, insurance coverage, and postpartum depression.

Results from a single-center, observational, prospective study suggested that inflammatory markers could predict disease severity and treatment efficacy for patients with spinal muscular atrophy (SMA).

The ending of the 2023 film “Barbie,” where she sees a gynecologist, has increased online search interest in gynecology; yesterday marked 34 years of the Americans With Disabilities Act (ADA); Texas Attorney General Ken Paxton is suing the Biden administration over Title X, a federal contraception program that provides teens birth control without parental consent.

These 48-week data from ARTISTRY-1 build on 24-week results previously presented and show enduring efficacy of bictegravir plus lenacapavir.

Health care inequity is costing the United States billions of dollars without providing quality outcomes for patients with rare and chronic diseases, Tiara Green, MSEd, president of Accessia Health, tells The American Journal of Managed Care.

In part 2 of our interview, Diane Mahoney, PhD, DNP, FNP-BC, WHNP-BC, APRN, advocates for a multidisciplinary, community-centered approach to reduce ovarian cancer care disparities and stresses the need for ongoing exploration of social, biological, and environmental factors affecting health outcomes.

The phase 3, international, open-label, single-group XTEND-Kids study concluded that children with severe hemophilia A younger than 12 years benefited from treatment with efanesoctocog alfa prophylaxis.

Liz Kwo, MD, MBA, MPH, chief commercial officer, Everly Health, and faculty lecturer, Harvard Medical School, discusses current and future uses in digital health care.

For Minority Mental Health Awareness Month, the Employee Benefits Security Agency (EBSA) in the US Department of Labor highlights the critical need to address mental health disparities among racial and ethnic minorities.

A new report shows wide variability in terms of which patients with chronic thromboembolic pulmonary hypertension (CTEPH) are deemed eligible for pulmonary endarterectomy and balloon pulmonary angioplasty.

Ryan Jacobs, MD, lymphoma division director at Atrium Health Levine Cancer Institute, explains the design and objectives of the phase 2 CAPTIVATE study comparing ibrutinib and venetoclax in patients with chronic lymphocytic leukemia (CLL).

Efforts to regulate social media for youth face resistance; MK-1654 meets key goals in mid-to-late stage trial; active drug shortages remain above 300 for sixth consecutive quarter.

Patients with intellectual disabilities experience inconsistent chronic obstructive pulmonary disease (COPD) consultations and higher rates of antibiotic prescriptions for asthma, highlighting the need for improved and tailored primary care management.

The phase 3 PEGASUS trial found that patients with paroxysmal nocturnal hemoglobinuria (PNH) may still experience anemia following recommended therapies, underscoring the need for further research.

Mark Bleackley, PhD, chief scientific officer of Incannex, discusses in further detail the need for a pharmacotherapy like IHL-42X in obstructive sleep apnea (OSA) and the medication's underlying mechanisms.

A new report offers safety and efficacy data on a population with generalized myasthenia gravis (gMG) not represented in the drug’s pivotal phase 3 trial.

A cross-sectional study found that static pain measures could be useful for predicting fatigue severity in patients with sickle cell disease (SCD).

Researchers of a new study explore what areas of chronic lymphocytic leukemia (CLL) treatment and care are important to patients and identify key areas for improvement.

For this analysis, investigators were interested in patient non–small cell lung cancer (NSCLC)–related outcomes from antibiotic administration before immunotherapy alone or immunotherapy and chemotherapy.

Liz Kwo, MD, MBA, MPH, chief commercial officer, Everly Health, and faculty lecturer, Harvard Medical School, discusses ways that wearable devices and health apps are improving value-based care.

A new report provided updated figures estimated the birth prevalence of spinal muscular atrophy (SMA) in the US.

A literature review plus in-person visits helped identify barriers to quality rheumatoid arthritis care, as well as effective interventions to improve care quality.

Almost half of all Americans struggle to afford quality health care and prescription medications; the cyberattack on UnitedHealth Group's Change Healthcare unit will cost the company between $2.3 billion and $2.45 billion in 2024; CMS releases the final part 2 guidance for plan outreach and education for the Medicare Prescription Payment Plan.

Investigators hoped to use large-scale proteomics to help predict hypertensive disorders of pregnancy (HDP), using blood proteins obtained from individuals in their first trimester of pregnancy—but success has been elusive.

In this interview from our coverage of the European Hematology Association 2024 Congress, we spoke with Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd, executive vice president and chief medical officer of the CLL Society and himself a survivor of chronic lymphocytic leukemia (CLL), to discuss treatment advancements and the importance of addressing both unmet needs and patient treatment preferences.

Ron Grunstein, MD, PhD, head of sleep and circadian research, Woolcock Institute of Medical Research, details results from the ALKS 2680 trial and the study's next steps.